Memantina Tecnigen

Memantine Hydrochloride, the active ingredient in Memantina Tecnigen, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, aiming to improve cognitive function and daily activities.

GNH USA supplies Memantina Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Memantina Tecnigen is used in the management of Alzheimer’s disease, targeting glutamatergic excitotoxicity.

Alzheimer's disease (moderate to severe): improves cognition, functional abilities and global clinical status. Dementia associated with Alzheimer's disease (moderate to severe): helps maintain daily living activities. Behavioral symptoms of Alzheimer's disease (moderate to severe): may reduce agitation and aggression.

Memantina Tecnigen may be associated with a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: transient disorientation.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Seizures: new‑onset or worsening of existing seizure activity. - Hypertension: marked increase in blood pressure requiring medical attention.

When prescribing Memantina Tecnigen, clinicians should consider several precautionary measures.

Renal impairment: dose adjustment may be required in patients with reduced kidney function. Hepatic disease: monitor liver enzymes as metabolism may be affected. History of seizures: use with caution, as the drug can lower seizure threshold. Concurrent use with other NMDA antagonists: avoid duplication of pharmacologic effect. Pregnancy and lactation: safety not established; weigh potential benefits against risks. Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Memantina Tecnigen can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neuropsychiatric adverse effects. - Ketamine: additive NMDA blockade can lead to excessive sedation or psychotomimetic effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may blunt cognitive benefits of memantine. - CNS depressants (e.g., benzodiazepines): monitor for enhanced sedation. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase memantine plasma levels.